A Multi-Institutional Experience in Pediatric High-Grade Glioma by Steve Walston et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 18 February 2015
doi: 10.3389/fonc.2015.00028
A multi-institutional experience in pediatric high-grade
glioma
SteveWalston1, Daniel A. Hamstra2, Kevin Oh3, GaryWoods4, Michael Guiou1, Randal S. Olshefski 4,
Arnab Chakravarti 1 andTerence M.Williams1*
1 Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
2 Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI, USA
3 Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
4 Department of Hematology-Oncology, Nationwide Children’s Hospital, Columbus, OH, USA
Edited by:
Minesh P. Mehta, Northwestern
University, USA
Reviewed by:
Sunit Das, University of Toronto,
Canada
Maria Caffo, University of Messina,
Italy
*Correspondence:
Terence M. Williams, Department of
Radiation Oncology, The Ohio State
University Comprehensive Cancer
Center-James Cancer Hospital,
Solove Research Institute, 460 West
10th Avenue Room D252Q,
Columbus, OH 43210, USA
e-mail: terence.williams@osumc.edu
Introduction:Pediatric high-grade gliomas are rare tumors with poor outcomes and incom-
pletely defined management. We conducted a multi-institutional retrospective study to
evaluate association of clinical, pathologic, and treatment characteristics with outcomes.
Materials and methods: Fifty-one patients treated from 1984 to 2008 at the Ohio State
University or University of Michigan were included. Histologic subgroups were compared.
Log-rank and stepwise Cox proportional hazard modeling were used to analyze progression-
free survival (PFS) and overall survival (OS) within the whole group, grade III subgroup,
grade IV subgroup, and sub-total resection/biopsy subgroup.
Results: Median OS was 27.6 months. Grade III histology, complete tumor resection, and
cerebral tumor location correlated with improved PFS and OS. Temozolomide use and
chemotherapy after radiotherapy or chemoradiation (CRT) were associated with better
PFS while seizure at presentation was associated with better OS. In multivariate analysis,
complete resection and chemotherapy following radiotherapy or CRT were independent
predictors for improved PFS and OS. For grade III and IV subgroups, complete resection
was associated with improved OS (grade III) and seizure presentation was associated with
improved OS (grade IV). In the incompletely resection subgroup, temozolomide use and
concurrent CRT independently correlated with improved PFS, while higher radiation dose
(≥59.4 Gy) and adjuvant chemotherapy were independently associated with improved OS.
Discussion: Total resection and receiving chemotherapy adjuvant to radiation or CRT are
most closely associated with improved PFS and OS. For higher risk incompletely resected
patients, temozolomide use and treatment intensification with concurrent CRT, adjuvant
chemotherapy, and higher radiation dose were associated with improved outcomes.
Keywords: high-grade glioma, glioblastoma, pediatric cancer, chemotherapy, radiation therapy
INTRODUCTION
High-grade gliomas (HGG) consist of grade III or IV tumors
arising from glial cell origin, including anaplastic astrocytoma,
anaplastic oligodendroglioma, glioblastoma, mixed glioma (1). In
children, the incidence is approximately 0.85 per 100,000 pop-
ulation and they are generally estimated to account for 8–12%
of childhood brain tumors (1, 2). When brainstem tumors are
excluded, the location is most commonly supratentorial with
about 35–50% of these tumors arising within the cerebral hemi-
spheres (2, 3). Less commonly, tumors occur in the thalamus,
hypothalamus, third ventricle, and basal ganglia (2, 3). The stan-
dard of care remains multimodal, utilizing a combination of
surgery, radiation therapy (RT), and chemotherapy (2, 4). How-
ever, despite aggressive treatment, survival remains poor with
a 5-year overall survival (OS) for anaplastic astrocytoma and
glioblastoma typically ~30 and 15–20%, respectively (1).
The current treatment paradigm includes maximal safe
resection as the primary treatment (2). Several prospective and
retrospective series have highlighted the prognostic importance
of maximizing extent of surgical resection (2, 5–7). Furthermore,
midline tumor location rather than posterior fossa or cerebral
hemisphere location has been associated with a worse progno-
sis perhaps due to decreased accessibility and extent of resection
(6). Due to the infiltrative nature of HGG, a true complete resec-
tion, even when radiographic resection is evident, is unlikely and
local recurrence is the dominant pattern of failure (2, 3, 8). There-
fore, adjuvant treatment including RT and chemotherapy remain
important for improving outcomes as further widening of surgi-
cal margins would result in unacceptable morbidity (2, 3, 6, 8). In
addition, the value of temozolomide with RT has not been clearly
established with randomized data in pediatric HGG, despite fre-
quent use based on extrapolation from benefit seen with adult
glioblastoma (9). Other issues surrounding the proper manage-
ment of pediatric HGG include the use of adjuvant chemotherapy
after RT or chemoradiation (CRT), and the appropriate radiation
dose.
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Due to the rarity of pediatric HGGs, it is difficult to con-
duct single institutional analyses to assess whether certain patient,
tumor, or treatment characteristics affect outcome. Thus, in order
to validate existing prognostic factors and identify novel prognos-
tic factors for pediatric HGGs, two institutional experiences were
pooled and analyzed. To our knowledge, this represents the largest
retrospective study of pediatric HGG.
MATERIALS AND METHODS
We conducted a multi-institutional, retrospective IRB-approved
study of 51 pediatric patients with HGG who were consecutively
treated at the Ohio State University or the University of Michi-
gan between 1984 and 2008. Brainstem gliomas were omitted
from the study due to lack of histological diagnosis. Pre-treatment
(patient), tumor, and treatment characteristics were collected on
all patients from review of electronic and paper charts. Patient,
tumor, and treatment characteristics were evaluated for the whole
cohort and were also broken down by histologic grade subgroups
(Table 1). Categorical variables between grade III and IV sub-
groups were compared using the Fisher’s exact t -test. A univariate
analysis (UVA) was performed on these characteristics to ana-
lyze for factors determining improved progression-free survival
(PFS) and OS in the whole cohort and each histological sub-
group (Table 2), as well as a subgroup consisting of non-gross
total resection (GTR) patients (Table 3). Factors evaluated include
age, gender, presenting symptoms, duration of symptoms, tumor
location, tumor size, histologic tumor grade, year treated, extent of
resection, radiation dose, and type and timing of chemotherapy.
OS and PFS were determined using the Kaplan-Meier method.
The log-rank test was used to identify factors associated with
improved PFS or OS and p< 0.05 was considered significant.
Patients lost to follow-up were censored. Multivariate analysis
(MVA) was performed with Cox proportional regression using
prognostic factors identified in the UVA (Tables 4 and 5). SPSS,
version 20 (SPSS Inc., Chicago, IL, USA) was used to perform the
statistical analyses.
Table 1 | Patient, tumor, and treatment characteristics for the entire cohort, grade III subgroup, and grade IV subgroup.
Factors Whole cohort (n=51) Grade III (n=23) Grade IV (n=28) Fisher exact t -test
Median age 13 (4−20) 13 (4−18) 13 (5−20) NA
Median follow-up 19 (2−269) 31 (5−269) 15.5 (2−142) NA
Gender
Male 55% (n = 28) 48% (n = 11) 61% (n = 17) p=0.41
Female 45% (n = 23) 52% (n = 12) 39% (n = 11) p=0.41
Duration of symptom presentation
≥6 weeks 35% (n = 18) 52% (n = 12) 21% (n = 6) p=0.73
<6 weeks 31% (n = 16) 39% (n = 9) 30% (n = 7) p=0.73
Symptoms at presentation
Headache 61% (n = 31) 61% (n = 14) 61% (n = 17) p=1.0
Seizure 31% (n = 16) 35% (n = 8) 29% (n = 8) p=0.76
Cranial nerve deficit 14% (n = 7) 13% (n = 3) 14% (n = 4) p=1.0
Location
Cerebrum 69% (n = 35) 78% (n = 18) 61% (n = 17) p=0.23
Thalamus 16% (n = 8) 9% (n = 2) 21% (n = 6) p=0.27
Midbrain 4% (n = 2) 4% (n = 1) 3.5% (n = 1) p=1.0
Cerebellum 6% (n = 3) 0% (n = 0) 11% (n = 3) p=0.60
Other 6% (n = 3) 9% (n = 2) 3.5% (n = 1) p=0.58
Size
Median (cm) 5 (2.5−10) 5 (2.5−7) 5 (3−10) NA
Extent of resection
Biopsy only 18% (n = 9) 13% (n = 3) 21% (n = 6) p=0.49
STR 59% (n = 30) 65% (n = 15) 54% (n = 15) p=0.57
GTR 23% (n = 12) 22% (n = 5) 25% (n = 7) p=1.0
Radiation and chemotherapy treatment
Median dose of RT 59.4 Gy 59.4 Gy 59.4 Gy NA
Concurrent CRT 51% (n = 26) 17% (n = 4) 79% (n = 22) p<0.0001
CT after RT/CRT 57% (n = 35) 61% (n = 14) 54% (n = 15) p=0.77
Concurrent and adjuvant CT 35% (n = 18) 13% (n = 3) 54% (n = 15) p=0.003
Temozolomide use 39% (n = 20) 4% (n = 1) 68% (n = 19) p<0.0001
NA, not applicable; GTR, gross total resection; STR, sub-total resection; RT, radiation therapy; CT, chemotherapy; CRT, chemoradiation.
Bold indicates significant value (p≤0.05).
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Table 2 | Univariate analysis for the entire cohort, grade III subgroup, and grade IV subgroup for PFS and OS.
Factors PFS OS
Whole cohort Grade III Grade IV Whole cohort Grade III Grade IV
p-value p-value p-value p-value p-value p-value
Patient characteristics
Age (≤13 vs. >13 years) 0.854 0.537 0.881 0.139 0.095 0.681
Gender (male vs. female) 0.843 0.601 0.471 0.632 0.805 0.282
Symptom duration (<6 vs. ≥6 weeks) 0.594 0.361 0.528 0.379 0.696 0.364
Headache (yes vs. no) 0.351 0.850 0.193 0.272 0.237 0.540
Seizure (yes vs. no) 0.097 0.463 0.008 0.019 0.340 0.016
Nerve deficit (yes vs. no) 0.131 0.718 0.082 0.139 0.541 0.035
Tumor characteristics
Grade IV vs. grade III 0.041 NA NA 0.011 NA NA
Location (cerebrum vs. other) 0.029 0.242 0.045 0.002 0.040 0.044
Size (>5 cm vs. ≤5 cm) 0.494 0.474 0.190 0.878 0.792 0.925
Treatment characteristics
Year treated (before 1997 vs. 1997 or after) 0.822 0.126 0.529 0.972 0.131 0.527
Extent of resection (STR/biopsy vs.GTR) 0.026 0.347 0.031 0.004 0.006 0.130
Concurrent CRT (yes vs. no) 0.759 0.656 0.997 0.786 0.412 0.491
CT after RT/CRT (yes vs. no) 0.003 0.905 0.681 0.001 0.211 0.589
Temozolomide (yes vs. no) 0.032 0.137 0.006 0.309 0.214 0.336
Concurrent and adjuvant CT (yes vs. no) 0.566 0.475 0.403 0.879 0.438 0.947
Radiation dose (≥59.4 vs. <59.4 Gy) 0.696 0.592 0.592 0.392 0.065 0.739
NA, not applicable; STR, sub-total resection; GTR, gross total resection; CT, chemotherapy; RT, radiation therapy; CRT, chemoradiation.
Bold indicates significant value (p≤0.05).
Table 3 | Univariate analysis for the STR/biopsy only subgroup.
Factors PFS OS
Whole cohort Grade III Grade IV Whole cohort Grade III Grade IV
p-value p-value p-value p-value p-value p-value
Grade IV vs. grade III 0.041 NA NA 0.011 NA NA
Concurrent CRT (yes vs. no) 0.851 0.617 0.470 0.769 0.940 0.697
CT after RT/CRT (yes vs. no) 0.006 0.545 0.257 0.001 0.162 0.980
Temozolomide (yes vs. no) 0.080 0.066 0.828 0.354 0.350 0.541
Concurrent and adjuvant CT (yes vs. no) 0.205 0.375 0.795 0.286 0.473 0.507
RT dose (≥59.4 vs. <59.4 Gy) 0.598 0.967 0.018 0.203 0.421 0.027
NA, not applicable; CT, chemotherapy; RT, radiation therapy; CRT, chemoradiation.
Bold indicates significant value (p≤0.05).
RESULTS
PATIENT CHARACTERISTICS AND SURVIVAL
Median follow-up for the whole cohort was 19 months from diag-
nosis. The 1- and 2-year OS rates were 78 and 53%, respectively,
and the median survival (MS) was 27.6 months (Figure 1A).
Table 1 shows patient characteristics for the whole cohort, as well
as for grade III and grade IV tumors, with statistical comparisons
between grade III and IV tumor groups. Histologic distribution
was 45% (n= 23) grade III and 55% (n= 28) grade IV. All patients
were under 21 years old with a median age at diagnosis of 13 years
(range 4–20) and 55% were males. Tumor location was cerebrum
(n= 35), thalamus (n= 8), midbrain (n= 2), cerebellum (n= 3),
and other (n= 3; foramen of Monro/ventricle, suprasellar, and
not available). All patients received at least CT scans for staging,
82% received MRI staging and post-treatment MRI scans. Analy-
sis for duration of symptom presentation was dichotomized at the
median of 6 weeks. The most common presenting symptoms were
headache 61% (n= 31), seizure 31% (n= 16), and cranial nerve
deficit 14% (n= 7). Other factors were also dichotomized by the
median for the UVA including age (13 years), tumor size (5 cm),
year treated (1997), and radiation dose (59.4 Gy).
Extent of surgical resection was defined by the surgeon, post-
operative imaging, or both in all cases and consisted of GTR 23%
(n= 12), sub-total resection (STR) 59% (n= 30), and biopsy only
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Table 4 | Multivariate analysis for the entire cohort and grade III/IV
subgroups.
Adjusted HR 95% CI p-value
WHOLE COHORT
Progression-free survival (PFS)
Grade IV vs. grade III 0.573 0.278–1.181 0.131
Cerebrum vs. other 1.623 0.719–3.665 0.244
STR/biopsy vs. GTR 0.262 0.089–0.775 0.015
CT after RT/CRT (yes vs. no) 3.391 1.526–7.218 0.002
Temozolomide (yes vs. no) 1.513 0.746–3.068 0.251
Overall survival (OS)
Grade IV vs. grade III 0.540 0.241–1.210 0.135
Cerebrum vs. other 1.621 0.710–3.701 0.252
STR/biopsy vs. GTR 0.202 0.060–0.683 0.010
Seizure vs. no seizure 1.431 0.528–3.880 0.482
CT after RT/CRT (yes vs. no) 4.187 1.856–9.442 0.001
Grade III
Progression-free survival (PFS)
Cerebrum vs. other 1.97 0.586–6.645 0.273
STR/biopsy vs. GTR 0.57 0.128–2.571 0.467
Overall survival (OS)
Cerebrum vs. other 1.81 0.519–6.286 0.353
STR/biopsy vs. GTR 0.16 0.034–0.743 0.019
Grade IV
Progression-free survival (PFS)
Seizure vs. no seizure 3.26 0.969–10.991 0.056
Cranial nerve deficit (yes vs. no) 0.38 0.110–1.316 0.127
Cerebrum vs. other 1.52 0.625–3.716 0.354
STR/biopsy vs. GTR 0.64 0.143–2.887 0.564
Temozolomide (yes vs. no) 2.49 0.896–6.898 0.080
Overall survival (OS)
Seizure vs. no seizure 4.20 1.181–14.969 0.027
Cranial nerve deficit (yes vs. no) 0.57 0.133–2.009 0.383
Cerebrum vs. other 1.75 0.613–4.969 0.297
STR/biopsy vs. GTR 0.99 0.216–4.520 0.988
Temozolomide (yes vs. no) 1.24 0.418–3.705 0.694
STR, sub-total resection; GTR, gross total resection; CT, chemotherapy; RT,
radiation therapy; RT, chemoradiation.
Bold indicates significant value (p≤0.05).
18% (n= 9). All patients received RT within 4 weeks following
resection and the median dose for the whole cohort was 59.4 Gy
in 33 fractions (range, 41.4–72 Gy in 23–60 fractions). In the
analysis, radiation dose was dichotomized by <59.4 Gy (n= 21
patients) vs.≥59.4 Gy (n= 30 patients). An almost equal percent-
age of patients in the grade III and grade IV groups received at
least 59.4 Gy [grade III 61% (n= 14), grade IV 57% (n= 16)].
Forty-two (82%) patients received chemotherapy as part of treat-
ment either concurrent with radiation only 51% (n= 26), after
RT or CRT 69% (n= 35), or both 35% (n= 18). Twenty patients
(39%) received temozolomide as part of their chemotherapy
[31% (n= 16) concurrent and adjuvant, 4% (n= 2) concurrent
only, 4% (n= 2) adjuvant only], eight (16%) patients received
Table 5 | Multivariate analysis for the STR/biopsy only subgroup.
Adjusted HR 95% CI p-value
Progression-free survival (PFS)
Grade IV vs. grade III 0.48 0.220–1.034 0.061
RT dose (≥59.4 vs. <59.4 Gy) 1.28 0.445–3.687 0.647
Temozolomide (yes vs. no) 8.81 2.397–32.401 0.001
CT after RT/CRT (yes vs. no) 1.61 0.581–4.443 0.361
Concurrent CRT (yes vs. no) 6.25 1.75–23.809 0.005
Concurrent and adjuvant CT
(yes vs. no)
2.83 0.812–9.892 0.102
Overall survival (OS)
Grade IV vs. grade III 0.42 0.173–1.004 0.051
RT dose (≥59.4 vs. <59.4 Gy) 2.84 1.129–7.137 0.027
Temozolomide (yes vs. no) 1.72 0.761–3.862 0.193
CT after RT/CRT (yes vs. no) 2.67 1.093–6.541 0.031
Concurrent CRT (yes vs. no) 1.72 0.477–6.173 0.408
Concurrent and adjuvant CT
(yes vs. no)
1.43 0.301–6.822 0.651
CT, chemotherapy; RT, radiation therapy; CRT, chemoradiation.
Bold indicates significant value (p≤0.05).
concurrent vincristine, six patients (12%) received adjuvant vin-
cristine, lomustine, and prednisone (pCV), and five (10%) patients
received adjuvant procarbazine, lomustine, and vincristine (PCV).
Alternate chemotherapy regimens were used in less than 10% of
the patients. The median number of adjuvant chemotherapy cycles
was seven.
In the grade III subgroup, the median age was 13 years, with a
median follow-up of 31.0 months. The MS was 31.0 months, and
the 1- and 2-year survival rates were 87 and 59%, respectively
(Figure 1B). In the grade IV subgroup, median age was 13 years,
with a median follow-up of 15.5 months. The MS for grade IV
tumors was 22.9 months, with 1- and 2-year OS rates of 71 and
48%, respectively (Figure 1B). Furthermore, the OS difference
between grade III and IV was statistically significant (p= 0.011)
with UVA. As shown in Table 1, patients with grade III tumors
received aggressive treatment regimens significantly less often with
lower rates of concurrent CRT [17% (n= 4) vs. 79% (n= 22);
(p< 0.0001)] and concurrent CRT plus adjuvant chemotherapy
[13% (n= 3) vs. 54% (n= 15); (p= 0.003)]. However, those with
grade III histology received adjuvant chemotherapy after RT or
CRT with a similar frequency compared to grade IV patients [grade
III 61% (n= 14); grade IV, 54% (n= 15)]. Temozolomide use was
significantly less common in grade III patients compared to grade
IV patients [4% (n= 1) vs. 68% (n= 19); (p< 0.0001)].
ANALYSIS OF PROGNOSTIC FACTORS IN WHOLE COHORT
The UVA for the whole group and each histologic subgroup is
shown in Table 2. In the whole cohort, factors that significantly
predicted for improved PFS were: grade III histology, cerebral loca-
tion, GTR, receiving chemotherapy after RT/CRT, and receiving
temozolomide as part of their chemotherapy regimen. The fac-
tors that predicted for significantly improved OS were identical to
PFS, except use of temozolomide was not significant. Additionally,
seizure at presentation predicted for improved OS, where there
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FIGURE 1 | (A) Overall survival for the whole cohort; (B) Overall survival for
the grade III and grade IV subgroups.
was only a trend in the PFS analysis. A MVA was performed using
prognostic factors identified in the UVA (Table 4). The only fac-
tors that maintained significance for PFS were GTR [p= 0.015,
HR 0.26 (95% CI 0.09–0.78)] and not having received chemother-
apy after RT/CRT [p= 0.002, HR 3.39 (95% CI 1.53–7.22)]. The
same factors were independent predictors for improved OS: GTR
[p= 0.01, HR 0.20 (95% CI 0.06–0.68)] and not having received
chemotherapy after RT/CRT [p= 0.001, HR 4.19 (95% CI 1.86–
9.44)]. Interestingly, histologic grade was not found to be an
independent predictor of PFS or OS.
SUBGROUP ANALYSIS OF PROGNOSTIC FACTORS BY GRADE OR
EXTENT OF RESECTION
Within the grade III subgroup, UVA revealed no factors with
significant impact on PFS, but cerebral location and GTR signif-
icantly predicted for improved OS (Table 2). MVA demonstrated
that GTR was the only factor which continued to show signifi-
cance for improved OS [p= 0.019, HR 0.16 (95% CI 0.034–0.74),
Table 4]. Within the grade IV subgroup, several factors were
significant for improvement in PFS and OS with UVA. Seizure at
presentation, cerebral location, GTR, and treatment with temo-
zolomide were associated with improved PFS, while seizure at
presentation, absence of cranial nerve deficit at presentation, and
cerebral location were associated with improved OS. MVA found
no associations with these factors for improved PFS, and only lack
of seizure at presentation was significantly associated with worse
OS compared to those who presented with seizure [p= 0.027, HR
4.20 (95% CI 1.18–14.97), Table 4].
The majority of the patients in this study, 77% (n= 39), did not
receive a GTR and an additional subgroup analysis was performed
on these patients. Of these, 23% (n= 9) underwent biopsy only
and 77% (n= 30) received STR. Given the strong prognostic value
associated with GTR, we hypothesized that certain treatment vari-
ables such as chemotherapy or radiation could impact PFS or OS
in the setting of incomplete resection. In this group, the median
RT dose was 59.4 Gy, 51% (n= 20) received concurrent CRT,
59% (n= 23) received chemotherapy after RT/CRT, 41% (n= 16)
received both concurrent and adjuvant chemotherapy, and 38%
(n= 15) received temozolomide. UVA was performed on grade
and treatment factors in this STR/biopsy subgroup (Table 3). As
previously noted with the whole cohort analysis, grade III patients
and patients who received chemotherapy following RT/CRT had
significantly improved PFS and OS. When focusing on the grade III
patients within the STR/biopsy subgroup, no factors were signifi-
cant for PFS or OS. For the grade IV patients within the STR/biopsy
subgroup, the only significant factor was radiation dose, with those
patients receiving either the median dose (59.4 Gy) or higher
demonstrating improved PFS and OS. Finally, a MVA was per-
formed on the STR/biopsy subgroup with these same treatment
factors and tumor grade (Table 5). Treatment with temozolomide
or concurrent CRT was significantly associated with improved
PFS, while higher radiation dose and chemotherapy given after
RT/CRT were significant for improved OS.
DISCUSSION
Although MS is typically higher than that of adults, outcomes
for pediatric HGGs remain poor. Due to their rarity, studies
directed at identifying prognostic, clinical, or pathological fac-
tors and optimal treatment strategies are difficult. Consequently,
adult treatment strategies, such as the use of concurrent temozolo-
mide and RT, are often extrapolated to children even though there
is data indicating these diseases are biologically distinct (10). By
pooling institutional datasets, our study represents the largest ret-
rospective evaluation of pediatric HGGs to our knowledge, which
has facilitated improved detection of prognostic factors and also
hypothesis-generating subgroup analyses.
Comparing our institutional results to others, the OS in our
patients appears to be similar to recent randomized studies in
pediatric HGG. As with our study, these trials typically group both
grade III and grade IV patients together. For example, the MS and
5-year OS for CCG-945 and our study were 26 vs. 27.6 months
and 36% vs. 34%, respectively (6). Thus, our dataset is applic-
able to pediatric patients treated in the current era. Our analysis
revealed that certain treatment variables, including extent of resec-
tion, concurrent and adjuvant chemotherapy, and radiation dose
were prognostic of outcomes in the whole group or in subgroup
analyses. We elaborate on these factors below.
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Although randomized controlled trials for degree of resection
are unlikely to be conducted, a more complete resection has been
correlated with improved PFS and OS in numerous studies (2, 5–
7, 11). This finding was corroborated in our study. Achieving a
GTR is associated with a significant improvement in both PFS and
OS in the total group, improved PFS in the grade IV subgroup,
and OS in the grade III subgroup. Furthermore, tumors involving
the cerebral hemispheres were associated with an improved OS
in all three populations (whole cohort, grade III, and grade IV),
which could relate to better accessibility for complete resection
(6). Cerebral hemisphere location also significantly improved PFS
in the grade IV patients as well as the whole cohort. However,
on MVA, GTR retained significance for PFS and OS, while tumor
location did not. This result was recently observed in a retrospec-
tive study which consisted of 27 pediatric grade IV patients: both
tumor location and extent of resection were significant on UVA,
but only extent of resection was independently correlated with OS
on MVA (11).
The use of any adjuvant chemotherapy, following RT/CRT
improved PFS and OS in both univariate and multivariate analy-
ses for the whole group. However, chemotherapy drug regimens
varied widely in our population. Despite this, 82% of patients
(n= 42 total; 65% of grade III patients, 96% of grade IV patients)
did receive chemotherapy, with 39% (n= 20) receiving temozolo-
mide. It is generally assumed that the addition of chemotherapy
after radiation improves outcome, but this has not been established
in a prospective, randomized trial. In CCG-943, CRT with vin-
cristine followed by 48 weeks of pCV vs. radiation alone resulted in
improved 5-year event-free survival of 46% vs. 18% (5). However,
this randomized trial altered two variables by adding both concur-
rent and adjuvant chemotherapy, which prevented the determina-
tion of independent benefits for either adjuvant or concurrent
chemotherapy. In our cohort, temozolomide was a frequent com-
ponent of treatment for grade IV patients with 68% (n= 19)
receiving this drug either concurrent with radiation only (n= 2),
adjuvant to radiation only (n= 2), or both (n= 15). Compar-
atively, only 4% (n= 1) of grade III patients were treated with
temozolomide. Interestingly, there was significantly improved PFS
for the patients who received temozolomide in both the total group
and grade IV subgroup, though this was not significant on MVA.
No OS advantage was observed, which was possibly due to the
significant grade imbalance: 95% of the patients who received
temozolomide had grade IV histology which predicted for worse
OS on UVA. In ACNS0126, a single-arm phase II study, using
concurrent and adjuvant temozolomide in pediatric patients with
grade IV glioma, no benefit was detected in PFS or OS when com-
pared to the CCG-945 patients who received either pCV-based
CRT or eight-drugs-in-one-based therapy (12). However, due
to reduced toxicity compared to other regimens, temozolomide-
based treatment has been widely adopted and will likely be used as
the platform in future trials. It is important to recognize MGMT
overexpression is a negative prognostic factor for HGG and temo-
zolomide may be more effective in those patients with decreased
enzyme expression or promoter methylation (13, 14). One poten-
tial limitation of our study was that MGMT status was not available
in our analysis. Taken together, our data suggest that adjuvant
chemotherapy and/or temozolomide may improve outcomes.
In our study, 51% of patients received concurrent CRT com-
pared to radiation alone. The benefit of adding chemotherapy to
radiation in a concurrent fashion compared to radiation alone has
also not been directly tested in pediatric trials. Since concurrent
CRT is the present standard of care, it is unlikely a trial enrolling
an arm seemingly inferior to the standard will ever be tested (2).
However, despite the improved outcome with combined modality
treatment demonstrated in previous randomized trials, concur-
rent CRT did not show a benefit in our retrospective cohort (4,
5). In addition, there was no difference noted in outcomes for
the 35% of patients who received both concurrent and adjuvant
chemotherapy (which is currently the standard of care for adult
and pediatric HGG patients) (2, 9). A possible explanation for this
lack of association is that the CRT group was enriched with neg-
ative prognostic variables including STR/biopsy (77%) and grade
IV histology (85%), and the patients given CRT followed by adju-
vant chemotherapy were composed of 86% grade IV tumors. Even
with these imbalances, no differences were observed in PFS or OS.
Thus, it would appear in this limited analysis, that these intensi-
fied treatment regimens might have acted to offset the imbalances
between the grade III and grade IV groups, resulting in equivalency
in outcomes.
Adjuvant radiation remains a standard of care due to the inva-
sive nature of HGGs, high local failure rate after surgery, and
morbidity with more extensive surgery in the brain (4). Typically,
50–60 Gy has been delivered to pediatric patients after surgery,
with the majority of clinical trials using a dose of 54 Gy in 30
fractions (5, 6, 12). Efforts to improve outcomes with hypo- or
hyper-fractionation have been unsuccessful or have not consis-
tently shown benefit (2, 15). Every patient in our study received
adjuvant RT with a median dose for the whole cohort and all
subgroups of 59.4 Gy. We found receiving a dose at or above the
median dose of 59.4 Gy was not associated with benefit in grade
III, grade IV, or the whole cohort. Interestingly, for the subgroup
of patients with incomplete resection, radiation dose at or above
the median dose of 59.4 Gy did show a significant improvement in
PFS and OS in the grade IV patients. Moreover, the higher dose of
radiation remained significant for improved OS with MVA. As a
result of STR, these patients are at higher risk for local recurrence.
Therefore, it is attractive to speculate that escalation of local ther-
apy could offer improvement in outcomes. As suggested by our
findings, it may be prudent to escalate the dose to at least 59.4 Gy
for grade IV patients who are unable to achieve a GTR.
In general, grade IV tumors tend to have a worse PFS and
OS when compared with grade III tumors, and the majority of
pediatric trials have included both histologies in their treatment
schema (2, 5, 6, 12). As compared with grade III disease, grade IV
tumors are more rapidly proliferating, demonstrate a more aggres-
sive infiltrative pattern, and may be more treatment resistant,
which all portend a worse prognosis. Our results are commen-
surate with previous reports, as patients with grade IV histology
had decreased PFS and OS compared with grade III, though this
did not reach significance on MVA. However, in patients who had
an incomplete resection, lower tumor grade was associated with
improved PFS on UVA and significantly improved OS on UVA and
MVA. Patients presenting with a seizure had a better OS on UVA
in the whole cohort and the grade IV subgroup and this remained
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significant for the grade IV subgroup. It is possible these patients
had less aggressive biology or more favorable tumor location as
57% of grade IV patients presenting with seizure had GTR while
only 25% of all grade IV patients had a GTR.
In summary, GTR and administration of chemotherapy after
RT/CRT were found to be the most significant predictors for PFS
and OS, each remaining significant on MVA for the whole group.
Interestingly, grade was not significant for the whole group on
MVA, perhaps since grade IV patients were enriched with patients
who received temozolomide and treatment intensification, includ-
ing concurrent CRT or concurrent and adjuvant chemotherapy.
Thus, the more intense treatments may have served to equal-
ize outcomes between grade III and grade IV tumors. In non-
GTR patients, adjuvant chemotherapy appeared to significantly
improve outcomes in MVA. Finally, in the grade IV patients within
the STR/biopsy subgroup, dose escalation to ≥59.4 Gy signifi-
cantly improved OS on MVA. Due to its retrospective design,
there are inherent limitations to this study which make it pos-
sible that certain outcomes are subject to confounding factors
that were unaccounted for. Specifically, we were unable to con-
trol for selection bias, accurate reporting of toxicities, low patient
numbers, performance status, MGMT methylation status, or other
genetic factors that would be better accounted for in prospective
trials. Also, there was no central pathologic review, which has
been shown in several CCG/COG studies to significantly alter
histological designation (16). Furthermore, even though treat-
ment in different eras did not appear to impact outcome using a
dichotomous variable (Table 2), it remains possible that there was
variation in diagnostic evaluation, histologic definition/criteria,
radiation/surgical technique, chemotherapy, or quality of sup-
portive care which may have impacted outcomes. Thus, additional
validation of these prognostic factors prospectively and/or in larger
datasets is warranted. Future clinical studies building upon a reg-
imen that includes radiation with concurrent and adjuvant TMZ
could consider stratifying by molecular factors, extent of resection,
grade, and potentially the other risk factors elucidated here. Our
results suggest that efforts to enhance tumor resection in order
to achieve GTR, possibly through improved pre-surgical imaging
techniques or intraoperative brain mapping, may improve out-
come. Furthermore, adjusting the length and/or type of adjuvant
chemotherapy or treatment intensification in high-risk groups
(possibly with radiation dose escalation) could be valid directions
for further study.
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